1. Home
  2. ANVS vs FORA Comparison

ANVS vs FORA Comparison

Compare ANVS & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

N/A

Current Price

$2.56

Market Cap

111.3M

Sector

Health Care

ML Signal

N/A

Logo Forian Inc.

FORA

Forian Inc.

N/A

Current Price

$2.08

Market Cap

66.2M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ANVS
FORA
Founded
2008
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
111.3M
66.2M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
ANVS
FORA
Price
$2.56
$2.08
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$13.50
N/A
AVG Volume (30 Days)
314.1K
16.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
62.92
N/A
EPS
N/A
N/A
Revenue
N/A
$20,153,263.00
Revenue This Year
N/A
$51.82
Revenue Next Year
N/A
$7.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.11
$1.64
52 Week High
$5.50
$2.71

Technical Indicators

Market Signals
Indicator
ANVS
FORA
Relative Strength Index (RSI) 46.57 46.32
Support Level $2.27 $2.05
Resistance Level $2.63 $2.12
Average True Range (ATR) 0.19 0.02
MACD 0.03 0.00
Stochastic Oscillator 34.62 40.00

Price Performance

Historical Comparison
ANVS
FORA

About ANVS Annovis Bio Inc.

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.

About FORA Forian Inc.

Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.

Share on Social Networks: